Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.
PR Newswire - December 11, 1995
The phase I trial with HGP-30 will evaluate safety and HIV-1 directed immune responses in HIV infected individuals. The trial will include 22 HIV patients with CD4 counts between 50 and 600. Each patient will receive three immunizations of the HGP-30 HIV immunogen during the course of six months. Previous clinical phase I studies with HGP-30 in 38 non-infected volunteers have already been successfully concluded in the United Kingdom and California.
Rights to the HGP-30 technology are owned by Viral Technologies, Inc., a 100% owned subsidiary of CEL-SCI Corporation. CEL-SCI Corporation has pioneered the development of Multikine(TM) for treatment of cancers and other immunodeficiency diseases.
CONTACT: Geert Kersten, Chief Executive Officer of CEL-SCI CORPORATION, 703-549-5293; or Gregory Britt, Chief Executive Officer of AIDS RESEARCH Alliance, 310-358-2423/ 08:45 EST
Copyright (c) 1995/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
951211
PR951219
Copyright © 1995 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .